blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1481992

EP1481992 - Humanized antibodies that sequester amyloid beta peptide [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.09.2017
Database last updated on 07.04.2026
Most recent event   Tooltip08.09.2017No opposition filed within time limitpublished on 11.10.2017  [2017/41]
Applicant(s)For all designated states
WASHINGTON UNIVERSITY ST. LOUIS
1 Brookings Drive, St. Louis
Missouri 63110 / US
For all designated states
Eli Lilly & Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
[2016/44]
Former [2004/49]For all designated states
WASHINGTON UNIVERSITY ST. LOUIS
1 Brookings Drive
St. Louis Missouri 63110 / US
For all designated states
Eli Lilly & Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
Inventor(s)01 / Holtzman, David, M.
368 Sunway
St. Louis MO 63141 / US
02 / Demattos, Ronald
Ap.12S
4949 West Pine Boulevard
St. Louis MO 63110 / US
03 / Bales, Kelly, R.
6376 S. 1000 E.
Cloverdale IN 46120 / US
04 / Paul, Steven, M.
1145 Laurelwood
Carmel IN 46032 / US
05 / Tsurushita, Naoya
3719 Redwood Circle
Palo Alto CA 94306 / US
06 / Vasquez, Maximiliano
3813 Louis Road
Palo Alto CA 94303 / US
 [2016/44]
Former [2004/49]01 / Holtzman, David, M.
368 Sunway
St. Louis MO 63141 / US
02 / Demattos, Ronald
Ap.12S 4949 West Pine Boulevard
St. Louis MO 63110 / US
03 / Bales, Kelly, R.
6376 S. 1000 E.
Cloverdale IN 46120 / US
04 / Paul, Steven, M.
1145 Laurelwood
Carmel IN 46032 / US
05 / Tsurushita, Naoya
3719 Redwood Circle
Palo Alto CA 94306 / US
06 / Vasquez, Maximiliano
3813 Louis Road
Palo Alto CA 94303 / US
Representative(s)Lee, Nicholas John, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[N/P]
Former [2016/44]Lee, Nicholas John, et al
Kilburn & Strode LLP 20 Red Lion Street
London WC1R 4PJ / GB
Former [2006/20]Chapman, Paul William
Kilburn & Strode, 20 Red Lion Street
London WC1R 4PJ / GB
Former [2006/18]Ford, Timothy James
Kilburn & Strode 20 Red Lion Street
London WC1R 4PJ / GB
Former [2006/10]Schnappauf, Georg, et al
Dr. Volker Vossius Patent- und Rechtsanwaltskanzlei Geibelstrasse 6
81679 München / DE
Former [2004/49]Grund, Martin, Dr., et al
Dr. Volker Vossius, Patentanwaltskanzlei, Geibelstrasse 6
81679 München / DE
Application number, filing date04011466.226.02.2001
[2004/49]
Priority number, dateUS20000184601P24.02.2000         Original published format: US 184601 P
US20000254465P08.12.2000         Original published format: US 254465 P
US20000254498P08.12.2000         Original published format: US 254498 P
[2004/49]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP1481992
Date:01.12.2004
Language:EN
[2004/49]
Type: A3 Search report 
No.:EP1481992
Date:08.12.2004
[2004/50]
Type: B1 Patent specification 
No.:EP1481992
Date:02.11.2016
Language:EN
[2016/44]
Search report(s)(Supplementary) European search report - dispatched on:EP22.10.2004
ClassificationIPC:C07K16/18, C12N15/13, C12N5/10, A61K39/00, A61P25/28
[2004/49]
CPC:
C07K16/18 (EP,KR,US); A61K39/39533 (NO); A61P25/00 (EP);
A61P25/28 (EP); A61K2039/505 (EP,US); C07K2317/24 (EP,US);
C07K2317/34 (EP,US); C07K2317/565 (EP,US); C07K2317/567 (EP,US);
C07K2317/76 (EP,US); C07K2317/92 (EP,US) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2016/44]
Former [2004/49]AT,  BE,  CH,  CY,  DE,  DK,  ES,  FI,  FR,  GB,  GR,  IE,  IT,  LI,  LU,  MC,  NL,  PT,  SE,  TR 
Extension statesAL13.05.2004
LT13.05.2004
LV13.05.2004
MK13.05.2004
RO13.05.2004
SI13.05.2004
TitleGerman:Humanisierte Antikörper, die Amyloid Beta Peptid sequentrieren[2004/49]
English:Humanized antibodies that sequester amyloid beta peptide[2004/49]
French:Anticorps humanises sequestrant un peptide amyloide beta[2004/49]
Examination procedure13.05.2004Examination requested  [2004/49]
27.05.2005Despatch of a communication from the examining division (Time limit: M06)
27.03.2006Reply to a communication from the examining division
21.04.2006Despatch of a communication from the examining division (Time limit: M06)
26.01.2007Reply to a communication from the examining division
04.05.2007Despatch of a communication from the examining division (Time limit: M06)
21.12.2007Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
19.02.2008Reply to a communication from the examining division
01.06.2012Despatch of a communication from the examining division (Time limit: M06)
10.12.2012Reply to a communication from the examining division
15.10.2014Despatch of a communication from the examining division (Time limit: M06)
23.04.2015Reply to a communication from the examining division
16.03.2016Communication of intention to grant the patent
16.03.2016Fee for publishing/printing paid
12.04.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
20.05.2016Communication of intention to grant the patent
20.09.2016Fee for grant paid
20.09.2016Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP01913081.4  / EP1257584
Divisional application(s)EP16161726.1  / EP3070100
EP16196667.6  / EP3150633
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20010913081) is  16.01.2003
Opposition(s)03.08.2017No opposition filed within time limit [2017/41]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
20.02.2008Request for further processing filed
20.02.2008Full payment received (date of receipt of payment)
Request granted
27.03.2008Decision despatched
27.03.2006Request for further processing filed
24.03.2006Full payment received (date of receipt of payment)
Request granted
11.04.2006Decision despatched
Fees paidRenewal fee
13.05.2004Renewal fee patent year 03
13.05.2004Renewal fee patent year 04
04.02.2005Renewal fee patent year 05
06.02.2006Renewal fee patent year 06
05.02.2007Renewal fee patent year 07
13.02.2008Renewal fee patent year 08
13.02.2009Renewal fee patent year 09
16.02.2010Renewal fee patent year 10
15.02.2011Renewal fee patent year 11
15.02.2012Renewal fee patent year 12
12.02.2013Renewal fee patent year 13
12.02.2014Renewal fee patent year 14
11.02.2015Renewal fee patent year 15
05.02.2016Renewal fee patent year 16
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]   WINTER ET AL: "HUMANIZED ANTIBODIES", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 14, no. 6, 1996, pages 243 - 246, XP001005438, ISSN: 0167-4919 [Y] 1-13 * See pages 243-245 (Building humanized antibodies) *

DOI:   http://dx.doi.org/10.1016/0167-5699(93)90039-N
 [Y]   SEUBERT ET AL: "ISOLATION AND QUANTIFICATION OF SOLUBLE ALZHEIMER'S BETA-PEPTIDE FROM BIOLOGICAL FLUIDS", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 359, no. 6393, 24 September 1992 (1992-09-24), pages 325 - 327, XP000616173, ISSN: 0028-0836 [Y] 1-13 * See the antibody 266 *

DOI:   http://dx.doi.org/10.1038/359325a0
 [Y]   PILLOT ET AL: "Fusogenic properties of the C-terminal domain of the Alzheimer beta-amyloid peptide", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, 1996, pages 28757 - 28765, XP002299386 [Y] 1-13 * See references to the central domain (13-28) throughout the article *

DOI:   http://dx.doi.org/10.1074/jbc.271.46.28757
 [Y]   ST GEORGE-HYSLOP ET AL: "Antibody clears senile plaque", NATURE, vol. 400, July 1999 (1999-07-01), pages 116 - 117, XP002299786 [Y] 1-13 * See page 116 (clearance of amyloid-beta peptide) *

DOI:   http://dx.doi.org/10.1038/22006
 [PYD]   BARD ET AL: "Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 6, no. 8, August 2000 (2000-08-01), pages 916 - 919, XP002154518, ISSN: 1078-8956 [PYD] 1-13 * See the Summary *

DOI:   http://dx.doi.org/10.1038/78682
ExaminationWO9927944
   SCHENK D ET AL: "IMMUNIZATION WITH AMYLOID-BETA ATTENUATES ALZHEIMER-DISEASE-LIKE PATHOLOGY IN THE PDAPP MOUSE", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 400, 8 July 1999 (1999-07-08), pages 173 - 177, XP002942852, ISSN: 0028-0836, DOI: 10.1038/22124 [Y] 1-13 * See pages 243-245 (Building humanized antibodies) *

DOI:   http://dx.doi.org/10.1038/22124
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.